The Fragile X program is very early stage. There has been very little data published to date. The “planned” phase 2/3 pivotal trial is more Missling hype than reality. This program will take many years and millions of dollars to move to a regulatory review phase. I don’t think investors are assigning much if any value to Fragile X at this stage. Ditto for all of the other programs, including AD.
Sigma-1 activation has been researched for more than 40 years. Despite all the promise, nothing clinically meaningful has been developed or commercialized by any company. You have to wonder why.
The silence from Anavex is deafening. You have to wonder just how deep the rot goes.
I know you’re trying to see the bright side but I think you’re grasping at straws.
Market Data 
Markets 
